Balyasny Asset Management
CSTL icon

Balyasny Asset Management’s Castle Biosciences CSTL Stock Holding History

Balyasny Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,730
Closed -$395K – 2913
2025
Q1 		$395K Buy
+19,730
New +$488K ﹤0.01% 2353
2024
Q4 		– Sell
-41,367
Closed -$1.18M – 2830
2024
Q3 		$1.18M Buy
+41,367
New +$1.05M ﹤0.01% 1895
2024
Q2 		– Sell
-14,748
Closed -$327K – 2650
2024
Q1 		$327K Buy
+14,748
New +$321K ﹤0.01% 2227
2021
Q1 		– Sell
-5,726
Closed -$385K – 1807
2020
Q4 		$385K Buy
+5,726
New +$310K ﹤0.01% 1157

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Balyasny Asset Management's CSTL Position: Q2 2025 in Review

Balyasny Asset Management sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 19,730 shares — an estimated $395K sold.

Balyasny Asset Management first reported a position in CSTL in Q4 2020 and held it in 4 quarters. The position peaked at $1.18M in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Balyasny Asset Management reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 19,730 Castle Biosciences shares in Q2 2025, an estimated $395K.
  • Balyasny Asset Management first reported a position in Castle Biosciences in Q4 2020 and held it in 4 quarters.
  • Balyasny Asset Management's Castle Biosciences position peaked at $1.18M in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.